Background-Renin released by ischemia/reperfusion from cardiac mast cells activates a local renin-angiotensin system (RAS). This exacerbates norepinephrine release and reperfusion arrhythmias (ventricular tachycardia and fibrillation), making RAS a new therapeutic target in myocardial ischemia. Methods and Results-We investigated whether ischemic preconditioning (IPC) prevents cardiac RAS activation in guinea pig hearts ex vivo. When ischemia/reperfusion (20 minutes of ischemia/30 minutes of reperfusion) was preceded by IPC (two 5-minute ischemia/reperfusion cycles), renin and norepinephrine release and ventricular tachycardia and fibrillation duration were markedly decreased, a cardioprotective anti-RAS effect. Activation and blockade of adenosine A 2b /A 3 receptors and activation and inhibition of protein kinase C⑀ (PKC⑀) mimicked and prevented, respectively, the anti-RAS effects of IPC. Moreover, activation of A 2b /A 3 receptors or activation of PKC⑀ prevented degranulation and renin release elicited by peroxide in cultured mast cells (HMC-1). Activation and inhibition of mitochondrial aldehyde dehydrogenase type-2 (ALDH2) also mimicked and prevented, respectively, the cardioprotective anti-RAS effects of IPC. Furthermore, ALDH2 activation inhibited degranulation and renin release by reactive aldehydes in HMC-1. Notably, PKC⑀ and ALDH2 were both activated by A 2b /A 3 receptor stimulation in HMC-1, and PKC⑀ inhibition prevented ALDH2 activation. 
H ow critical mast cells are in cardiac pathophysiology is not well understood. Numerous mast cells are present in the mammalian heart (Ϸ50 000 mast cells per 1 g human heart tissue) in close proximity to vessels and nerves, and their density markedly increases in heart failure, ischemic cardiomyopathy, and experimental infarct models. 1 Mast cells synthesize, store, and release a variety of mediators. We recently reported that cardiac mast cells are also an important source of the aspartyl protease renin. 2 When released by ischemia/reperfusion (I/R), this renin initiates the activation of a local renin-angiotensin system (RAS); the locally formed angiotensin II (Ang II) exacerbates norepinephrine release from cardiac sympathetic nerves and elicits reperfusion arrhythmias. 3 When mast cells are depleted or pharmacologically stabilized, renin and norepinephrine release and reperfusion arrhythmias are markedly reduced. 3 Thus, the release of mast cell-derived renin represents a new target in the prevention and treatment of ischemic cardiac dysfunction.
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Brief ischemic exposures have repeatedly been shown to protect the heart both structurally and functionally from a subsequent prolonged exposure to I/R. Ischemic preconditioning (IPC), as this phenomenon is known, has been the object of wide attention since its discovery. 4 -6 Adenosine release and activation/translocation of protein kinase C (PKC) have been identified as necessary steps in the cardio-protection afforded by classic IPC (eg, infarct size reduction). 6 -8 Of the PKC family of serine/threonine kinases, the PKC⑀ isoform has been shown to play a key cardioprotective role against I/R 9,10 and to exhibit antisecretory activity in mast cells. 11 Accordingly, we set out to determine whether IPC might also prevent the activation of a local cardiac RAS initiated by the release of mast cell renin and, if so, whether this novel IPC paradigm involves the activation of PKC⑀ in mast cells. Given that phosphorylation of mitochondrial aldehyde dehydrogenase type-2 (ALDH2) by PKC⑀ correlates with cardioprotection, 12 we hypothesized that IPC could promote PKC⑀-induced activation of ALDH2, which would then remove the toxic aldehydes known to degranulate mast cells such as acetaldehyde and 4-hydroxynonenal (4-HNE), which are formed by lipid peroxidation. [13] [14] [15] Our study outlines a novel protective anti-RAS effect of IPC; we find that the sequential activation of adenosine A 2b and A 3 receptors, PKC⑀, and ALDH2 in cardiac mast cells diminishes the release of renin elicited by I/R and thus curtails Ang II-and norepinephrineinduced arrhythmias.
Methods
See the online-only Data Supplement for the complete Methods section.
Ex Vivo Hearts
In total, 132 male Hartley guinea pigs (weight, 300 to 350 g; Charles River Laboratories, Kingston, NY) were anesthetized with CO 2 and euthanized by stunning with approval from the Institutional Animal Care and Use Committee. Isolated hearts were perfused at constant pressure with oxygenated Ringer at 37°C in a Langendorff apparatus (Radnoti Glass Technology, Monrovia, Calif).
Ischemia/Reperfusion
After equilibration, all hearts were subjected to 20 minutes of global ischemia followed by 30 minutes of reperfusion. For IPC, two 5-minute cycles of ischemia were each followed by 5 minutes of reperfusion. For pharmacological prevention of IPC, antagonists were perfused for 20 minutes (glyceryl trinitrate [GTN] for 30 minutes) before and during IPC and then washed out for 15 minutes before I/R. For pharmacological preconditioning, given agents were perfused for two 5-minute cycles before I/R except for ␦V1-1 (PKC␦ inhibitor), which was administered during the entire 30-minute reperfusion following the 20-minute ischemia. For prevention of pharmacological preconditioning, antagonists were perfused for 20 minutes (GTN for 30 minutes) before and during pharmacological preconditioning and then washed out for 15 minutes before I/R.
Coronary flow was measured every 2 minutes; samples were assayed for renin, norepinephrine, ␤-hexosaminidase, and creatine phosphokinase (CPK). Surface ECG was obtained from the left ventricle and right atrium, recorded in digital format, and analyzed with Power Laboratory/8SP (AdInstrument, Colorado Springs, Colo).
Cell Culture
The human mastocytoma cell line (HMC-1) was a gift of from Dr I. Biaggioni (Vanderbilt University, Nashville, Tenn). Cells were maintained in suspension culture as previously described. 2 
␤-Hexosaminidase and Renin Assay
␤-Hexosaminidase and renin coronary overflow was measured as previously described. 3 HMC-1 cells were suspended in Ringer buffer, and equal volumes were divided into aliquots in Eppendorf tubes and incubated at 37°C with a given agent (ie, Alda-1, ⑀RACK, or LUF5835 plus IBMECA) for 10 minutes (preceded or not by a 30-minute incubation with GTN). Acetaldehyde, H 2 O 2 , or 4-HNE was subsequently added for 20 minutes. All results were normalized and expressed as percent above control.
Norepinephrine Assay
Coronary effluent was assayed for norepinephrine by highperformance liquid chromatography with electrochemical detection as previously described. 3 
CPK Assay
Coronary effluent was assayed for CPK release with a CPK assay kit (Genzyme Diagnostics, Charlottetown, Prince Edward Island, Canada).
Polymerase Chain Reaction and Immunostaining
For reverse-transcription polymerase chain reaction (RT-PCR), total RNA was extracted from HMC-1 cells with TRIzol reagent (Invitrogen, Carlsbad, Calif), 1 g total RNA from each sample was reverse transcribed, and complementary DNA was amplified by RT-PCR with a Qiagen (Valencia, Calif) 1-step RT-PCR kit. PCR products were analyzed by agarose gel electrophoresis and ethidium bromide staining. For immunostaining, HMC-1 cells were fixed and permeabilized on glass slides and stained with the goat anti-A 2b receptor antibody (Santa Cruz Biotechnology, Santa Cruz, Calif) conjugated to Alexa Fluor 488 donkey anti-goat IgG and with rabbit anti-A 3 receptor antibody (Santa Cruz) conjugated to Alexa Fluor 488 donkey anti-rabbit IgG. Nuclei were stained with DAPI. For immunofluorescence, cells were examined with an inverted fluorescence microscope (Nikon Eclipse TE 2000-U, Morrell Instruments, Melville, NY) interfaced to an electron multiplying charge-coupled device (Hamamatsu Photonics, Bridgewater, NJ) and processed with Metamorph software (version 6.2, Universal Imaging Corp, Downington, Pa).
Translocation of PKC⑀
Cytosolic and membrane fractions of HMC-1 cells were separated, and Western blot analysis was performed with a PKC⑀-specific antibody (Santa Cruz).
ALDH2 Enzymatic Activity Assay
ALDH2 activity in HMC-1 cells was determined spectrophotometrically by monitoring the reductive reaction of NAD ϩ to NADH at 340 nm as previously described. 16 
Drugs and Chemicals
Acetaldehyde, H 2 O 2 , IBMECA, MRS1754, MRS1523, DPCPX, chelerythrine, 5-hydroxydecanoate, and cyanamide were purchased from Sigma-Aldrich (St Louis, Mo); 4-HNE in ethanol solution was purchased from Cayman Chemical (Ann Arbor, Mich). LUF5835 was a gift from Dr M.W. Beukers (University of Leiden, Leiden, the Netherlands); EXP3174 was a gift from Merck Sharp & Dohme Ltd (Whitehouse Station, NJ); ⑀RACK, ␦V1-1, and Alda-1 were synthesized in Dr Mochly-Rosen's laboratory (Stanford University School of Medicine, Palo Alto, Calif). Phorbol 12-myristate 13-acetate was purchased from LC Laboratories (Woburn, Mass). GTN was purchased from Hospira Inc (Lake Forest, Ill). Human plasma angiotensinogen was purchased from Calbiochem (San Diego, Calif).
Statistics
Data are presented as meanϮSEM. Nonparametric tests were used throughout the study. For 2-group comparisons, the Mann-Whitney test was used (Figures 1 and 2 ). For comparisons among Ͼ2 groups, the Kruskal-Wallis test followed by the posthoc Dunn test was used (Figures 1 through 3, 4D , 4F, and 5 through 7). GraphPad Prism version 4.03 for Windows (GraphPad Software, San Diego, Calif) was used. Values of PϽ0.05 were considered statistically significant.
Results

IPC Prevents the Activation of a Cardiac RAS and Alleviates Arrhythmic Dysfunction
Spontaneously beating Langendorff-perfused guinea pig hearts were subjected to 20 minutes of global ischemia followed by 30 minutes of reperfusion. This resulted in mast cell degranulation, demonstrated by a 202Ϯ31% (nϭ5; meanϮSEM) increase in ␤-hexosaminidase overflow into the coronary effluent. I/R also caused large increases in renin and norepinephrine overflow (ie, Ϸ2.5-and Ϸ75-fold, respectively) and severe ventricular arrhythmias (tachycardia and fibrillation [VT/VF]) that lasted Ϸ12 minutes ( Figure 1) . We had previously shown that the enhanced norepinephrine overflow and arrhythmias result from the activation of a local RAS by renin released from cardiac mast cells. 3 When I/R was preceded by IPC (ie, two 5-minute cycles of ischemia, each followed by 5 minutes of reperfusion), mast cell degranulation was only approximately half that occurring with I/R alone, as indicated by a marked decrease in ␤-hexosaminidase overflow (ie, the overflow of ␤-hexosaminidase increased by 202Ϯ31% and 109Ϯ14% with I/R and I/R preceded by IPC, respectively; nϭ5 and 5; PϽ0.05). IPC also greatly reduced the overflow of renin and norepinephrine and the duration of VT/VF (ie, an overall Ϸ70% to 85% decrease; Figure 1 ), clearly indicating a cardioprotective anti-RAS effect of IPC. Notably, the overflow of renin and norepinephrine during preconditioning was only slightly and not significantly higher than that in nonconditioned hearts (renin overflow, 7.10Ϯ0.99 pg ⅐ h Ϫ1 ⅐ g Ϫ1 Ang I formed during IPC and 6.81Ϯ2.12 pg ⅐ h Ϫ1 ⅐ g Ϫ1 Ang I in control conditions; norepinephrine overflow, 3.82Ϯ1.17 pmol/g during IPC versus 4.02Ϯ0.77 pmol/g in control conditions; meanϮSEM; nϭ8ϩ6; Pϭ0.95 and Pϭ0.75 for renin and norepinephrine, respectively). Thus, the finding that IPC markedly attenuated the I/R-induced release of renin and norepinephrine was not due to depletion of renin and norepinephrine pools during preconditioning.
Combined Activation of Adenosine A 2b and A 3 Receptors Mimics the Cardioprotective Anti-RAS Effects of IPC Adenosine, PKC, and mitochondrial ATP-sensitive potassium channels (mK ATP ) have been identified as necessary steps in the cardioprotection afforded by classic IPC (eg, infarct size reduction). 6 -8 Furthermore, although Ang II is widely perceived as a deleterious agent, it has also been found to mimic the cardioprotective effects of IPC. [17] [18] [19] Thus, we investigated whether adenosine, mK ATP channels, Ang II, and PKC play a role in the cardioprotective anti-RAS IPC paradigm.
First, we assessed whether inhibition or activation of adenosine receptors prevents or mimics, respectively, the IPCmediated attenuation of renin release in hearts subjected to I/R. We found that the combined blockade of adenosine A 2b and A 3 receptors with the MRS1754 (50 nmol/L) 20 and MRS1523 (100 nmol/L) 21 compounds prevented the IPC-induced attenuation of renin and norepinephrine release and the alleviation of reperfusion arrhythmias ( Figure 1A) . Conversely, the combined activation of A 2b and A 3 receptors with the LUF5835 (50 nmol/L) 22 and IBMECA (50 nmol/L) 23 compounds mimicked the cardioprotective anti-RAS effects of IPC ( Figure 1A 24 was also ineffective ( Figure  1A) . Thus, only the combined activation of A 2b and A 3 receptors appears to induce the cardioprotective anti-RAS effects of IPC.
Because the opening of mK ATP channels is known to be involved in the mediation of classic IPC-induced cardioprotection, 7, 25, 26 we questioned whether these channels may also play a role in the anti-RAS effects of IPC. Thus, we induced IPC in the presence of the mK ATP antagonist 5-hydroxydecanoate (100 mol/L; IC 50 ϭ30 mol/L). 27 5-Hydroxydecanoate failed to affect the cardioprotective anti-RAS effects of IPC. In fact, the IPC-induced attenuation of renin and norepinephrine release and the abbreviation of reperfusion arrhythmias were the same in the presence and absence of 5-hydroxydecanoate ( Figure IA in the online-only Data Supplement). Hence, the cardioprotective anti-RAS effects of IPC do not appear to depend on the opening of mK ATP channels.
According to early reports in rabbits and rats, Ang II mimicked the cardioprotective effects of classic IPC. [17] [18] [19] Thus, we determined whether Ang II, which is locally produced in the heart subjected to I/R, 3 contributes to the anti-RAS effects of IPC. For this, we induced IPC in hearts perfused with the AT 1 receptor antagonist EXP3174. EXP3174 (300 nmol/L; IC 50 ϭ6 nmol/L) 28 
Translocation of PKC⑀ Mediates the Cardioprotective Anti-RAS Effects of Adenosine A 2b and A 3 Receptor Activation
Because PKC activation/translocation is likely to be involved in the cardioprotective effects of classic IPC, 8, 29 we next investigated the role of PKC in the cardioprotective anti-RAS Of the PKC family of serine/threonine kinases, the PKC⑀ isoform has been shown to play a key cardioprotective role against I/R. 9,10,30,31 Thus, we tested whether ⑀RACK, a selective activator peptide of PKC⑀, 32 mimics the anti-RAS effects of IPC. ⑀RACK (500 nmol/L), perfused for two 5-minute cycles followed by a 5-minute washout before I/R, mimicked the protective anti-RAS effects of IPC. Indeed, the overflow of renin and norepinephrine and the duration of VT/VF were reduced by Ϸ55% to 90% compared with I/R hearts ( Figure 1B ). Moreover, selective inhibition of PKC⑀ with ⑀V1-2 (1 mol/L) 33 prevented the effects of IPC on the same parameters ( Figure 1B ). Thus, PKC⑀ activation appears to be required and sufficient for the genesis of the cardioprotective anti-RAS effects of IPC.
Stimulation of adenosine A 2b and A 3 receptors mimicked the anti-RAS effects of IPC (see Figure 1A) ; selective activation of the PKC⑀ isoform also had anti-RAS effects similar to IPC (see Figure 1B ). Given that adenosine is known to activate PKC, thus initiating the traditional preconditioning cascade, 6 -8 we determined whether the anti-RAS IPC-like effects of A 2b and A 3 receptors rely on the consequent activation of PKC⑀. To verify this notion, we assessed whether PKC⑀ blockade would prevent the IPC-like effects of A 2b and A 3 receptor agonists. We found that selective inhibition of the PKC⑀ isozyme with ⑀V1-2 (1 mol/L) 33 prevented the anti-RAS IPC-like effects resulting from the combined activation of A 2b and A 3 receptors (Figure 2A ). Thus, A 2b and A 3 receptor-mediated activation of PKC⑀ appears to be the first significant step in the anti-RAS preconditioning pathway.
Activation of ALDH2 Is Pivotal for the Cardioprotective Anti-RAS Effects of PKC⑀
Because the cardioprotective infarct-sparing effects of PKC⑀ activation 30 have been found to depend on phosphorylation of mitochondrial ALDH2, 12, 34 we next assessed whether the anti-RAS effects of IPC are also determined by ALDH2 activation. For this, we assessed whether inhibition/inactivation of ALDH2 would abolish the anti-RAS effects of IPC and whether activation of ALDH2 would mimic them. We found that GTN, perfused for 30 minutes at a concentration known to inactivate ALDH2 (2 mol/L), 12 prevented the cardioprotective anti-RAS effects of ⑀RACK (ie, GTN abolished the ⑀RACK-induced inhibition of renin and norepinephrine release and the alleviation of VT/VF; Figure 2B ). We also found that the general ALDH inhibitors cyanamide (5 mmol/L) 12 and GTN prevented the anti-RAS effects of IPC ( Figure 3A and 3B) . Conversely, selective activation of ALDH2 with Alda-1 12,34 (20 mol/L, two 5-minute cycles) reproduced all of the anti-RAS effects of IPC, an action that was also prevented by cyanamide ( Figure 3A ) and by pretreatment with GTN ( Figure 3B ). Collectively, these findings suggest that ALDH2 activation by PKC⑀ is a crucial mechanistic step in the development of the anti-RAS effects of IPC.
Mast Cells Are the Site of the Cardioprotective Anti-RAS Action of IPC
Given the pivotal role that mast cells play in the activation of RAS in the heart, 3 cardiac mast cells are likely to be the site at which the anti-RAS effects of IPC develop. Because combined activation of adenosine A 2b and A 3 receptors mimics the cardioprotective anti-RAS effects of IPC, whereas the combined blockade of the same receptors prevents the anti-RAS effects (see Figure 1A) , we first ascertained the presence of A 2b and A 3 receptors on mast cells. For this, we used human mast cells in culture (HMC-1 cells). Total RNA (1 g) was extracted from HMC-1 cells, reverse transcribed, and amplified by PCR using sense and antisense primers specific for human A 2b and A 3 receptor genes. Figure 4A depicts an ethidium bromide-stained gel showing that the HMC-1 PCR products for these adenosine receptor subtypes are consistent with those reported by others. 35 HMC-1 cells were also immunopositive for the 2 adenosine receptor subtypes ( Figure 4B ).
We next made certain that mast cell PKC⑀ can be activated. Using Western analysis in cytosolic and membrane fractions of HMC-1 cells, we found that the phorbol ester PMA (positive control) markedly increased the translocation of PKC⑀ from cytosol to membrane (ie, a hallmark of PKC⑀ activation; Figure 4C through 4F). Incubation of HMC-1 cells with the PKC⑀ activator ⑀RACK (500 nmol/L for 30 minutes) before a 7-minute incubation with a below-threshold concentration of PMA (3 nmol/L) 36 also significantly translocated PKC⑀ from cytosol to membrane ( Figure 4C and 4D) . Moreover, incubating HMC-1 cells with the adenosine A 2b and A 3 receptor agonists in combination (LUF5835 and IBMECA, 50 nmol/L each for 1 hour) also translocated PKC⑀ ( Figure 4E and 4F).
Our findings in isolated guinea pig hearts and cultured mast cells suggested that IPC may result from the activation of adenosine A 2b and A 3 receptors expressed by cardiac mast cells and consequent PKC⑀-dependent activation of mitochondrial ALDH2. Thus, we next investigated the role of ALDH2 in mast cell degranulation and renin release elicited by prototypic toxic compounds formed in I/R. For this, we measured mast cell degranulation in response to acetaldehyde, 4-HNE, another toxic aldehyde that accumulates during cardiac ischemia, and hydrogen peroxide (H 2 O 2 ), which triggers toxic aldehydes formation by membrane lipid peroxidation. 13, 15 Incubation of HMC-1 cells with acetaldehyde (300 to 700 mol/L), H 2 O 2 (0.1 to 1 mmol/L), or 4-HNE (3 to 30 mol/L) elicited a concentration-dependent increase in the release of ␤-hexosaminidase (Ϸ15% to 42%, an indication of mast cell degranulation) and renin (Ϸ15% to 80%; Figure 5 ). Notably, preincubation of HMC-1 cells with the ALDH2 activator Alda-1 (20 mol/L) 12,34 prevented the degranulating effects of each acetaldehyde, H 2 O 2 , and 4-HNE (Figure 5A through 5F). Moreover, pretreatment of HMC-1 cells with the ALDH2 desensitizer GTN (2 mol/L for 30 minutes) prevented the antidegranulating effects of Alda-1 ( Figure 5 ). These findings suggested that ALDH2 activation in mast cells prevents their degranulation by toxic aldehydes produced in the I/R heart and that this represents a crucial mechanistic step in the anti-RAS effects of IPC.
We next measured ALDH2 activity in HMC-1 cells in response to the specific ALDH2 activator Alda-1, 37 the non-isoform-specific PKC activator PMA, the PKC⑀-selective agonist ⑀RACK, and the adenosine A 2b and A 3 receptor agonists in combination. We found that the ALDH2 enzymatic activity (ie, NADH production) was enhanced by Alda-1 (100 mol/L), PMA (300 nmol/L), ⑀RACK (0.5 and 1 mol/L), and LUF5835 (50 nmol/L) and IBMECA (50 nmol/L) combined ( Figure 6 ). Notably, selective PKC⑀ inhibition with ⑀V1-2 (1 mol/L) prevented the increase in ALDH2 activity elicited by A 2b and A 3 receptor agonists in combination ( Figure 6 ).
Given that activation of A 2b and A 3 receptors in HMC-1 cells increased ALDH2 activity and that this was inhibited by the PKC⑀ antagonist (see Figure 6 ), we next examined whether activation of A 2b and A 3 receptors and PKC⑀ would each protect mast cells from degranulation and renin release. We found that the large concentration-dependent increase in ␤-hexosaminidase and renin release elicited by incubation with H 2 O 2 (0.1 to 1 mmol/L) was markedly inhibited by LUF5835 (50 nmol/L) and IBMECA (50 nmol/L) combined ( Figure 7A and 7C) and by ⑀RACK (500 nmol/L; Figure 7B and 7D). These effects were prevented by prior ALDH2 desensitization with GTN pretreatment (2 mol/L for 30 minutes; Figure 7A through 7D) . Collectively, these findings indicate that activation of adenosine A 2b and A 3 receptors on the mast cell membrane leads to an increase in PKC⑀ activity and thus ALDH2 activation, which prevents the degranulating effects of toxic aldehydes such as those produced in I/R.
Finally, we sought to establish whether the cardioprotective anti-RAS effects of IPC, which most likely result from an action at the mast cell level, are independent of the IPCinduced reduction of myocyte damage. Because both PKC⑀ activation 10 and PKC␦ inhibition 32 protect cardiac myocytes from I/R-induced damage, we compared PKC⑀ activation with PKC␦ inhibition in terms of CPK release, as well as renin and norepinephrine release and VT/VF duration. We found that I/R (ie, 20 minutes of global ischemia followed by 30 minutes of reperfusion) caused a characteristic increase in CPK overflow into the coronary effluent of isolated guinea pig hearts that peaked between the 4th and 10th minutes of reperfusion ( Figure IIA in the online-only Data Supplement). IPC, ⑀RACK pretreatment (500 nmol/L, two 5-minute cycles), and reperfusion with the PKC␦ antagonist ␦V1-1 (500 nmol/L) each and all reduced total CPK overflow (0 to 20 minutes of reperfusion) by Ϸ50% ( Figure IIB in the online-only Data Supplement). However, whereas ⑀RACK pretreatment markedly reduced the activation of RAS, thus displaying cardioprotective anti-RAS effects, reperfusion with ␦V1-1 did not affect renin and norepinephrine release or alleviate VT/VF, thus failing to protect the heart from the consequences of mast cell degranulation, including induction of VT/VF ( Figure IIC in the online-only Data Supplement). These findings indicate that the cardioprotective anti-RAS effects of IPC are mediated by a separate pathway that is independent of cardiac myocyte salvage but directly dependent on the modulation of renin release from cardiac mast cells.
Discussion
The notion of a local tissue-specific RAS, in addition to the classic circulating RAS, has now gained general recognition. 38, 39 Renin, the rate-limiting step in RAS activation, has been found in cardiac myocytes, 38, 40 and renin mRNA has been identified in heart fibroblasts and endothelial and smooth muscle cells of coronary vessels. 38 Our laboratories recently demonstrated that mast cells can synthesize and secrete renin. 2,3 I/R causes the release of renin from cardiac mast cells, activating a local RAS, which results in severe arrhythmic dysfunction. 3 We have now uncovered a novel cardioprotective anti-RAS paradigm of IPC and delineated its transductional pathway. IPC prevents I/R-induced renin release from cardiac mast cells via an adenosine-mediated activation of PKC⑀ in these cells, followed by activation of mitochondrial ALDH2, which effectively prevents mast cell degranulation. Given the pivotal role played by mast cell renin in local RAS activation, [1] [2] [3] we propose that the cardioprotective anti-RAS effect of IPC, typified by a marked decrease in the overflow of ␤-hexosaminidase, renin, and norepinephrine, and the curtailing of VT/VF are based on an inhibitory action at the mast cell level. This novel IPC paradigm is unlike classic IPC. In classic IPC, myocytes are the main target of cardioprotection, and IPC is characterized by infarct-size reduction and improved recovery of contractility. 4 -6 Although the adenosine A 1 receptor has often been associated with IPC-induced protection of cardiac myocytes, 6, 8 we found here that the anti-RAS effects of IPC do not involve A 1 receptors because A 1 receptor blockade failed to modify the anti-RAS effects of IPC. This agrees with the reported lack of A 1 receptors in mast cells 41 and with our proposal that mast cells are the critical site at which the cardioprotective anti-RAS effects of IPC develop. Mast cells are known to express both adenosine A 2b and A 3 receptors 42, 43 (see also Figure 4 ). We found that the combined activation of A 2b and A 3 receptors displayed IPC-like effects: It attenuated the release of renin and norepinephrine and alleviated reperfusion arrhythmias associated with I/R. These cardioprotective anti-RAS effects were similar to those afforded by IPC, which in fact was abolished by blockade of adenosine A 2b and A 3 receptors in combination. Although A 2b and A 3 receptors are known as low-affinity receptors (K i Ն5 and 1 mol/L for A 2b and A 3 , respectively), 44 both were likely activated by endogenous adenosine during IPC. Indeed, interstitial adenosine was shown to reach a 7-mol/L level after 6 minutes of IPC in the isolated heart. 45 Significantly, the combined activation of A 2b and A 3 receptors in HMC-1 cells in culture also prevented peroxideinduced degranulation and renin release, supporting our conclusion that these mast cell receptors play a major role in the anti-RAS effects of IPC. Activation of either A 2b or A 3 receptor alone failed to mimic the cardioprotective effects of IPC, demonstrating the necessity that both receptors be activated for the initiation of IPC. Other actions of adenosine such as coronary dilatation have also been shown to require a concomitant activation of both A 2b and A 3 receptors. 46 That the activation of A 2b and A 3 receptors in HMC-1 cells prevents degranulation and renin release concurs with the protective antisecretory effect of A 2b receptors, demonstrated by enhanced mast cell activation when A 2b receptors are deleted in mice. 47 Yet, other investigators have shown that activation of A 2b and A 3 receptors promotes the release of mediators and cytokines from human lung fragments, rat RBL-2H3 cells, HMC-1 cells, and macrophages from A 2b receptor-deleted mice. 42, 43, 48 The discrepancy between these findings and ours most likely depends on differences in cells and animal species and on the different stimuli used to degranulate mast cells.
Opening of K ATP channels in the inner membrane of mitochondria in cardiac myocytes has been found to contribute to the protective effects of classic IPC. 6 -8 Yet, the mK ATP channel antagonist 5-hydroxydecanoate 27 failed to modify the cardioprotective anti-RAS effects of IPC, indicating that these mitochondrial channels are not involved in the mast cell-dependent anti-RAS effects of IPC.
Having established that activation of A 2b and A 3 receptors contributes to the anti-RAS effects of IPC, we asked whether A 2b and A 3 receptors might signal via PKC⑀, given that this isoform has both cardioprotective 9,10 and antisecretory properties in mast cell-like RBL-H3 cells. 11 Indeed, we found that selective blockade of PKC⑀ with ⑀V1-2 33 abolished the anti-RAS effects of IPC, whereas selective activation of PKC⑀ with ⑀RACK 10 mimicked them. Notably, the IPC-like anti-RAS effects of A 2b and A 3 receptor agonists in combination were prevented by selective PKC⑀ inhibition. Collectively, at this point, our findings suggested that the initial step in the anti-RAS signaling sequence of IPC could be an adenosine-induced stimulation of A 2b and A 3 receptors resulting in PKC⑀ translocation in cardiac mast cells. In fact, A 2b and A 3 receptor activation in HMC-1 cells caused the translocation of PKC⑀ from cytosol to membrane, the hallmark of PKC⑀ activation.
Acetaldehyde and 4-HNE are formed during I/R, 14, 15 in part by lipid peroxidation caused by reactive oxygen species such as hydrogen peroxide. 13 These toxic aldehydes, known to elicit mast cell degranulation, 49 can be removed by mitochondrial ALDH2, a phosphorylation target of PKC⑀. 12 Indeed, we found that Alda-1, a selective ALDH2-activating drug, 12,34,37 not only mimicked the cardioprotective anti-RAS effects of IPC in the guinea pig heart ex vivo but also prevented the degranulating effects of acetaldehyde, H 2 O 2 , and 4-HNE in HMC-1 cells in culture. These effects were abolished by selective inactivation of ALDH2 with GTN. Similarly, pretreatment of HMC-1 cells with GTN prevented the antidegranulating effects caused by activation of A 2b and A 3 receptors or PKC⑀. Hence, these findings add further support to the proposal that activation of ALDH2 in cardiac mast cells is the final crucial step of the protective anti-RAS pathway.
Because A 2b and A 3 receptors, PKC⑀, and ALDH2 are also present in cardiac myocytes, 37, 50 it is conceivable that in addition to mast cells, activation of ALDH2 in cardiac myocytes mediates cardioprotection from I/R. To rule out this possibility, we used the PKC␦ inhibitor ␦V1-1, which protects cardiac myocytes from damage by I/R 51 but does not affect mast cell degranulation (Palandiyani SS and MochlyRosen D, unpublished results). When we compared the cardioprotective effects resulting from PKC⑀ activation with those caused by PKC␦ inhibition, 32 we found that the mast cell-dependent anti-RAS effects of IPC were clearly separable from the protective effects on cardiac myocytes. One would have expected that the cardioprotective effects of PKC␦ inhibition might reduce reperfusion arrhythmias, if they were to originate mostly from myocytes. On the contrary, PKC␦ inhibition, which reduced myocyte damage by I/R to a similar extent as PKC⑀ activation, did not abolish reperfusion arrhythmias. Thus, mast cell renin release and RAS activation are the predominant cause of arrhythmic dysfunction in I/R, and activation of ALDH2 in mast cells is an important cardioprotective mechanism in ischemic conditions.
Cardiac myocytes have been reported to express all of the RAS components, including renin. 38, 40 Renin mRNA has also been found in heart fibroblasts and in endothelial and smooth muscle cells of coronary vessels. 38 Thus, it is conceivable that in addition to cardiac mast cells, myocytes and other cells in the heart may contribute to renin production and RAS activation in I/R. In fact, the incidence of reperfusion arrhythmias was markedly reduced, but not completely abolished, in hearts isolated from mice lacking mast cells or in guinea pig hearts perfused with mast cell-stabilizing agents. 3 This suggests that other cells in the heart could release renin in response to I/R.
Conclusions
We propose that adenosine released from various cells during I/R and IPC activates A 2b and A 3 receptors on the surface of cardiac mast cells and that this is followed by activation/ translocation of PKC⑀, which then increases the catalytic activity of mitochondrial ALDH2 (see Figure 8) . By eliminating reactive aldehydes and their mast cell-degranulating effects, ALDH2 prevents renin release and RAS activation. This reduces Ang II formation, inhibits excessive norepinephrine release, and prevents the generation of reperfusion arrhythmias. Notably, the relevance of our findings extends beyond the disclosure of a new IPC mechanism. Indeed, although the discovery of IPC has generated a wealth of studies, its clinical translation has yet to come to fruition. 52 As the search for cardioprotective drugs continues unabated, our findings elucidate novel basic mechanisms of pharmacological cardioprotection (ie, the detoxification of reactive aldehydes and ROS in I/R by increasing the catalytic activity of mitochondrial ALDH2, thus alleviating the dysfunctional consequences of RAS activation in the heart). This new finding suggests that in addition to protecting cardiac myocytes from I/R-induced injury, drugs that prevent cardiac mast cell degranulation may prevent the activation of a local RAS, thus providing an additional benefit to patients with myocardial infarction and perhaps in other cardiac oxidative stress conditions such as those occurring in heart failure. 
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CLINICAL PERSPECTIVE
Ischemia/reperfusion is a known cause of cardiac dysfunction that is often accompanied by infarction, contractile failure, and severe arrhythmias. The production of reactive oxygen species and reactive aldehydes is considered a prominent cause because aldehyde detoxification by mitochondrial aldehyde dehydrogenase type-2 displays cardioprotective effects. We recently reported that ischemia/reperfusion elicits the release of renin from cardiac mast cells, which in turn activates a local renin-angiotensin system, causing severe arrhythmic dysfunction. Reactive oxygen species and reactive aldehydes are likely responsible for mast cell degranulation and renin release; hence, means to prevent such effects could be clinically beneficial. We describe here a novel pathway that is independent of cardiomyocyte salvage and relies instead on aldehyde dehydrogenase type-2 activation in mast cell mitochondria. Aldehyde dehydrogenase type-2 detoxifies reactive aldehydes produced in ischemia/reperfusion, thus preventing mast cell degranulation and renin release. This avoids the activation of a local renin-angiotensin system and reperfusion arrhythmias. This new finding suggests that in addition to protecting cardiac myocytes from ischemia/reperfusion-induced injury, drugs that prevent cardiac mast cell degranulation may prevent the activation of a local renin-angiotensin system, thus providing an additional benefit to patients with myocardial infarction and perhaps in other cardiac oxidative stress conditions such as those occurring in heart failure. and then centrifuged at 1,000 g for 10 min. Supernatants were collected and kept in ice until β-hexosaminidase and renin release was evaluated. Cell pellets were lysed with 0.5% triton X-100 and centrifuged at 13,000 g. Supernatants were then used for protein and total β-hexosaminidase content determination. All results were normalized and expressed as percent above control.
Supplemental Materials MATERIALS AND METHODS
Animals
NE assay. Coronary effluent was assayed for norepinephrine by HPLC with electrochemical detection as previously described. 3 The detection limit was approximately 0.2 pmol.
CPK assay. Coronary effluent was assayed for creatine phosphokinase release using a creatine kinase assay kit (Genzyme Diagnostics, Charlottetown, PE, Canada). Substrate and buffer reagent were added to the collected coronary effluent and then incubated at with 1% Triton X-100, and then centrifuged at 100,000 g for 30 min to collect membrane fractions (supernatant). Translocation of PKCε was assessed by using a PKCε-specific antibody (Santa Cruz; 1:1000 dilution) in Western blot analysis. Methods for Western blot analysis were as previously described. 3 The ratio of PKCε in membrane to that in cytosol was expressed as PKCε translocation.
ALDH2 enzymatic activity assay. Enzymatic activity of ALDH2 in HMC-1 cells was determined spectrophotometrically by monitoring the reductive reaction of NAD + to NADH at 340 nm as previously described. 4 The assays were carried out in 50 mmol/L sodium pyrophosphate buffer, pH = 9.0, at 25 o C. 300 µg of cell lysates and 2.5 mmol/L NAD were added to the buffer. 
